ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025)
ENDRA Life Sciences' (NDRA) quarterly Current Deferred Revenue came in at $328610.0 in Q2 2025, down 15.9% quarter-over-quarter from $390722.0 in Q1 2025.
Powered by 
Analysis
ENDRA Life Sciences (NDRA) Current Deferred Revenue (2024 - 2025) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Current Deferred Revenue for 2 consecutive years, with $328610.0 the latest figure, recorded in Q2 2025.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $328610.0 in Q2 2025; TTM through Jun 2025 was $328610.0, a N/A change from a year earlier, with the FY2024 full-year figure at $799284.0, changed N/A from the prior year.
- Current Deferred Revenue was $328610.0 for Q2 2025 at ENDRA Life Sciences, down from $390722.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $910556.0 in Q3 2024 and troughed at $328610.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | GE HealthCare Technologies | 28.97 Bn | 27.09 Bn | 2.18 Bn |
| 2 | Lantheus Holdings | 6.56 Bn | 5.97 Bn | 241.86 Mn |
| 3 | Heartflow | 4.40 Bn | 4.03 Bn | 53.19 Mn |
| 4 | Neogen | 2.83 Bn | 2.64 Bn | 107.80 Mn |
| 5 | Butterfly Network | 1.88 Bn | 1.75 Bn | 23.29 Mn |
| 6 | Ceribell | 931.50 Mn | 802.24 Mn | 25.94 Mn |
| 7 | Varex Imaging | 779.32 Mn | 694.02 Mn | 76.70 Mn |
| 8 | Anbio Biotechnology | 755.43 Mn | 743.53 Mn | - |
| 9 | QuidelOrtho | 725.35 Mn | 601.95 Mn | - |
| 10 | ENDRA Life Sciences | 8.25 Mn | 2.71 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 328,610.00 |
| Mar 31, 2025 | 390,722.00 |
| Dec 31, 2024 | 799,284.00 |
| Sep 30, 2024 | 910,556.00 |